Novo Nordisk is currently facing litigation over its popular diabetes medication, Ozempic. The pharmaceutical giant has been accused of failing to adequately warn users about the potential risk of blindness. The lawsuit has been initiated by a Maryland resident who reportedly developed non-arteritic anterior ischemic optic neuropathy after using the drug. This condition, while having an unclear origin, is generally attributed by medical professionals to the reduced blood supply or ischemia affecting the optic nerve, alleges the claimants in the lawsuit.
For further details on these allegations, the developments can be followed through reporting by the New Jersey Law Journal.